Sunday, July 27, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

The FDA Just Approved a Long-Lasting Injection to Prevent HIV

Simon Osuji by Simon Osuji
June 20, 2025
in Artificial Intelligence
0
The FDA Just Approved a Long-Lasting Injection to Prevent HIV
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


The US Food and Drug Administration has just approved lenacapavir, an injectable form of HIV prevention that is almost 100 percent effective and requires only two doses per year. Science magazine described the medicine the most important scientific advance of 2024.

In clinical trials, lenacapavir proved to be 99.9 percent effective in preventing HIV infection through sexual transmission in people weighing more than 35 kilograms. The drug, an antiretroviral, works not by stimulating an immune response, but by blocking HIV from reproducing during its early stages—specifically, by disrupting the function of the virus’s capsid protein. This happens so long as the body receives injections every six months.

Lenacapavir has already been approved in some countries as a treatment for HIV in people with forms of the virus that are resistant to other treatments. However, prior to this week, its prophylactic use had not been approved anywhere, making the FDA’s decision a significant new development in the fight against the HIV/AIDS epidemic.

The drug is not the first medicine that can be taken preemptively to protect against an HIV infection: pre-exposure prophylaxis (PrEP) pills were already available in many countries, including the United States. But these must be taken every day, and ensuring ongoing access to these medicines, and that people actually remember to take them, is a known challenge. It’s hoped the long-lasting effects of lenacapavir will make it easier for people to stay protected against the virus.

According to its creator, Gilead Sciences, lenacapavir will be marketed under the trade name Yeztugo. The company has committed to manufacturing 10 million doses by 2026.

“This is a historic day in the decades-long fight against HIV. Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic,” Daniel O’Day, president and CEO of Gilead, said in a statement on Wednesday.

However, lenacapavir’s price may be a barrier to access. Yeztugo will have an annual list price of $28,218 per person in the US. Winnie Byanyima, executive director of of the Joint United Nations Program on HIV/AIDS (UNAIDS), has also flagged in the past that the drug is unaffordable for many people in Africa, where the medicine has the potential to have the biggest impact. Roughly two-thirds of the people living with HIV worldwide live in sub-Saharan Africa.

Gilead said in a statement last year that it had been “developing a strategy to enable broad, sustainable access globally” to lenacapavir, although the company has not yet provided detailed information on how it will do this. One option could be “voluntary licensing,” where other companies are granted permission to produce and sell generic versions of a patented product exclusively to people in certain (often low-income) countries. Researchers at the University of Liverpool in the UK have calculated that a year’s worth of lenacapavir could be made available for as little as $25.

This story originally appeared on WIRED en Español and has been translated from Spanish.



Source link

Related posts

TCL QM8K Review: The Best Mid-Tier TV

TCL QM8K Review: The Best Mid-Tier TV

July 27, 2025
A ‘Grand Unified Theory’ of Math Just Got a Little Bit Closer

A ‘Grand Unified Theory’ of Math Just Got a Little Bit Closer

July 27, 2025
Previous Post

Nigeria’s largest container terminal receives first LNG-powered vessel

Next Post

How Gov Ododo is leveraging multilateral partnership to transform road infrastructure?

Next Post
How Gov Ododo is leveraging multilateral partnership to transform road infrastructure?

How Gov Ododo is leveraging multilateral partnership to transform road infrastructure?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Orioles agree to settle part of MASN pay dispute with Nationals: Sources

Orioles agree to settle part of MASN pay dispute with Nationals: Sources

2 years ago
Labour Government brings opportunities and changes for our energy industry –

Labour Government brings opportunities and changes for our energy industry –

12 months ago
‘Let Us Stand United, Hand in Hand’

‘Let Us Stand United, Hand in Hand’

6 months ago
Navigating the ‘Wild West’ of EV Charging

Navigating the ‘Wild West’ of EV Charging

11 months ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • The world’s top 10 most valuable car brands in 2025

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • Top 10 African countries with the highest GDP per capita in 2025

    0 shares
    Share 0 Tweet 0
  • Global ranking of Top 5 smartphone brands in Q3, 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.